Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech announced results from an independent market assessment showing oncologists reported a high likelihood to prescribe Annamycin for relapsed/refractory AML, with an average score of 6 out of 7. Physicians cited deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key factors. (Items: 7.01 Regulation FD Disclosure On June 5, 2026, Moleculin Biotech, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MBRX